Bristol Myers Squibb Target of Unusually Large Options Trading (NYSE:BMY)

Bristol Myers Squibb Company (NYSE:BMY) was the target of unusually large options trading activity on Thursday. Traders bought 34,923 call options on the company. This is an increase of 49% compared to the typical daily volume of 23,471 call options.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The FDA accepted Bristol Myers Squibb’s NDA for mezigdomide in relapsed/refractory multiple myeloma, a meaningful regulatory step that could strengthen the company’s oncology pipeline and future revenue prospects. Bristol Myers Squibb (BMY) Wins FDA Review For Mezigdomide In Multiple Myeloma
• Positive Sentiment: Unusual options activity showed traders buying a notably higher-than-average number of call options, suggesting some investors are positioning for additional upside in BMY.
• Positive Sentiment: Recent commentary highlighted Bristol Myers Squibb as a strong value stock, reinforcing the view that the shares may still look attractive on valuation grounds. Here’s Why Bristol Myers Squibb (BMY) is a Strong Value Stock
• Neutral Sentiment: Brokerage coverage continues to point to a “Hold” consensus, indicating analysts are not broadly turning more bullish or bearish on the stock. Bristol Myers Squibb Company (NYSE:BMY) Receives Consensus Rating of “Hold” from Brokerages
• Neutral Sentiment: Erste Group slightly lowered its FY2027 EPS estimate to $6.10 from $6.12, but the change is modest and still near consensus, so it is unlikely to be a major near-term driver by itself.
• Negative Sentiment: The small downward revision to longer-term earnings expectations may indicate some caution around Bristol Myers Squibb’s post-2026 growth trajectory, which could limit enthusiasm if investors focus on future profitability.

Bristol Myers Squibb Trading Up 0.3%

Bristol Myers Squibb stock opened at $60.71 on Friday. The firm has a 50-day moving average price of $57.02 and a two-hundred day moving average price of $57.78. Bristol Myers Squibb has a 52-week low of $42.52 and a 52-week high of $62.89. The firm has a market capitalization of $123.97 billion, a price-to-earnings ratio of 17.05, a PEG ratio of 0.17 and a beta of 0.23. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter in the prior year, the business posted $1.80 earnings per share. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Sell-side analysts expect that Bristol Myers Squibb will post 6.34 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 70.79%.

Analysts Set New Price Targets

BMY has been the subject of a number of recent analyst reports. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Cantor Fitzgerald restated a “neutral” rating and issued a $54.00 price target on shares of Bristol Myers Squibb in a research note on Monday, July 6th. Guggenheim reissued a “buy” rating and set a $72.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Finally, Bank of America decreased their price target on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a research note on Friday, July 10th. Eight analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Bristol Myers Squibb presently has an average rating of “Hold” and an average target price of $61.25.

Hedge Funds Weigh In On Bristol Myers Squibb

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BMY. Brighton Jones LLC lifted its stake in Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after buying an additional 4,935 shares in the last quarter. Sivia Capital Partners LLC lifted its position in shares of Bristol Myers Squibb by 59.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after acquiring an additional 2,786 shares in the last quarter. United Bank boosted its stake in Bristol Myers Squibb by 15.0% in the 2nd quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock worth $1,164,000 after purchasing an additional 3,277 shares during the period. Marshall Wace LLP purchased a new position in Bristol Myers Squibb during the 2nd quarter worth approximately $221,000. Finally, Nebula Research & Development LLC acquired a new stake in Bristol Myers Squibb during the 2nd quarter valued at $405,000. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.